The investment objective of the scheme is to provide returns that, before expenses, correspond to the total returns of the securities as represented by Nifty MidSmall Healthcare Total Return Index,
subject to tracking error.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| Index Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -7.23% | -4.05% | 9.75% | 12.99% | 9.33% | N/A | N/A | N/A | N/A | N/A | 8.5% |
| Category returns | -3.49% | -4.55% | -2.01% | -3.44% | -4% | -2.79% | 10.35% | 12.84% | 9.89% | 11.18% | N/A |
| Absolute returns | -7.23% | -4.05% | 9.75% | 12.99% | 9.33% | N/A | N/A | N/A | N/A | N/A | 16.91% |
| Rank within category | 214/216 | 60/207 | 11/199 | 8/193 | 10/184 | N/A | N/A | N/A | N/A | N/A | N/A |
| Index Funds | 2024 | 2025 | 2026 |
|---|---|---|---|
| Yearly returns | N/A | -1.48% | 10.68% |
| Q1 returns | N/A | -7.69% | -5.12% |
| Q2 returns | N/A | 6% | 19.99% |
| Q3 returns | N/A | -0.72% | 1.49% |
| Q4 returns | N/A | 1.42% | -4.21% |
1% on or before 15D, Nil after 15D
| Alpha | -0.0944999 |
| Beta | 0.9962 |
| Sharpe Ratio | 0.0987307 |
| Sortino Ratio | 0.189999 |
| R-Squared | 0.9954 |
| Tracking Error | 0.0669 |
| Downside Risk | 16.7516 |
| Std. Deviation (Annualised) | 15.0815 |
| Index Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICICI Prudential NASDAQ 100 Index Fund - Growth | -1.52% | 1.37% | 12.73% | 20.33% | 27.46% | 30.85% | 18.72% | N/A | 18.87% | 3,738.17 | 1.06 | 0.39 | Very High |
| Motilal Oswal S&P 500 Index Fund - Regular Plan - Growth | -0.5% | 1.6% | 10.19% | 15.5% | 24.15% | 26.62% | 16.54% | N/A | 19.94% | 4,584.30 | 1.04 | 0.44 | Very High |
| ICICI Prudential Nifty Pharma Index Fund - Regular Plan - Growth | -4.18% | -0.29% | 13.6% | 15.38% | 14.48% | 18.13% | N/A | N/A | 18.71% | 163.10 | 1.18 | 0.29 | Very High |
| UTI Nifty 500 Value 50 Index Fund - Regular Plan - Growth | -4.93% | -6.29% | -9.73% | -4.85% | 2.97% | 18.1% | N/A | N/A | 23.08% | 838.01 | 1.21 | 0.21 | Very High |
| Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund - Regular Plan - Growth | -4.3% | -1.59% | 11.56% | 11.09% | 13.2% | 17.83% | 12.7% | N/A | 14.93% | 191.85 | 1.10 | 0.32 | Very High |
| Motilal Oswal BSE Enhanced Value Index Fund - Regular Plan - Growth | -3.42% | -6.2% | -9.67% | -9.99% | -0.86% | 17.49% | N/A | N/A | 24.9% | 2,131.66 | 1.12 | 0.19 | Very High |
| Aditya Birla Sun Life Nifty Smallcap 50 Index Fund - Regular Plan - Growth | -4.83% | -1.02% | 10.76% | 12.27% | 8.48% | 15.62% | 10.2% | N/A | 15.72% | 364.19 | 1.11 | 0.18 | Very High |
| Kotak Nifty Smallcap 50 Index Fund - Regular Plan - Growth | -5.01% | -1.19% | 10.63% | 11.86% | 8.08% | 15.42% | N/A | N/A | 24.48% | 259.53 | 0.92 | 0.18 | Very High |
| ICICI Prudential Nifty Auto Index Fund - Regular Plan - Growth | -5.75% | -5.5% | -2.85% | -7.06% | -5.92% | 15.29% | N/A | N/A | 19.15% | 234.49 | 0.95 | 0.18 | Very High |
| Motilal Oswal Nifty MidSmall Healthcare Index Fund - Regular Plan - Growth Current | -7.23% | -4.05% | 9.75% | 12.99% | 9.33% | N/A | N/A | N/A | 8.5% | 52.54 | 1.21 | 0.10 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 11.83% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.57% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.09% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 6.15% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.39% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.78% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.35% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.11% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.96% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.54% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.23% |
| Krishna Institute of Medical Sciences Ltd | Healthcare Services | Domestic Equities | 3.06% |
| Aster DM Quality Care Ltd. | Healthcare Services | Domestic Equities | 2.86% |
| Neuland Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.82% |
| Wockhardt Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.68% |
| Acutaas Chemicals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.61% |
| Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.53% |
| Dr. Lal Pathlabs Ltd. | Healthcare Services | Domestic Equities | 2.38% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.17% |
| Piramal Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.97% |
| Granules India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.92% |
| Narayana Hrudayalaya Ltd. | Healthcare Services | Domestic Equities | 1.90% |
| Global Health Ltd. | Healthcare Services | Domestic Equities | 1.86% |
| Onesource Specialty Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.84% |
| Glaxosmithkline Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.76% |
| Anthem Biosciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.42% |
| Natco Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.14% |
| Cohance Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.11% |
| Syngene International Ltd. | Healthcare Services | Domestic Equities | 1.06% |
| Poly Medicure Ltd. | Healthcare Equipment & Supplies | Domestic Equities | 0.98% |
| Triparty Repo | Cash & Cash Equivalents and Net Assets | 0.76% | |
| Net Receivables / (Payables) | Cash & Cash Equivalents and Net Assets | -0.82% | |
| Total | 100.00% | ||
Mr. Swapnil Mayekar has more than 10 years of overall experience in the financial services industry. He has been part of fund management & product development team for Motilal Oswal Asset Management Company Ltd. Mr. Mayekar's key area of expertise is trading in equity and debt segment, quantitative analysis, creating customized indices, model testing and building research database. His last assignment was with Business Standard Limited as a Research Associate. He has done his post-graduation in Commerce (Finance Management) from University of Mumbai.
Mr. Rakesh Shetty has more than 13 years of overall experience and expertise in trading in equity, debt segment, Exchange Trade Fund’s management, Corporate Treasury and Banking. Prior to joining Motilal Oswal Asset Management Company Limited, he has worked with Company engaged in Capital Market Business wherein he was in charge of equity and debt ETFs, customized indices and has also been part of product development.
Mr. Dishant Mehta has more than 9 years of experience and expertise in Financial markets across different segment- Equities, Derivatives, Commodities and Currencies. Managed Institutional and Foreign Portfolio Investment clients.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
